3
Announcements
Trials
Browse
Landscape
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
24
Salivary Gland Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Biochemically Recurrent Prostate Cancer
1
Advanced Solid Tumor
1
Interventions
darolutamide
2
Docetaxel
2
Androgen Antagonists
2
niraparib
1
Prednisone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
×
darolutamide
×
90 days
×
Clear all
NCT07395804
2026-05-29
23146
Bayer
Recruiting
500 enrolled
NCT06661122
2026-05-19
HAYATE
Bayer
Recruiting
100 enrolled